John Dee Named Procept President and CEO
Succeeds Stanley Erck, Who Remains Consultant
CAMBRIDGE, Mass.--(BUSINESS WIRE)--February 11, 1998-- Procept, Inc. (Nasdaq: PRCT - news) today announced
that its Board of Directors has appointed John F. Dee as the Company's President and Chief Executive Officer, effective
immediately. Mr. Dee was also named a director of Procept.
In these capacities, Mr. Dee succeeds Stanley C. Erck, who resigned from Procept's management and board to pursue other
interests. Mr. Erck will remain a consultant to Procept for the next several months.
Mr. Dee, 40, has diverse experience in the health care and biotechnology fields. He was most recently interim Chief Executive
Officer of Genta Incorporated [Nasdaq:GNTA - news], where he led an intensive six-month corporate turnaround. Prior to
that, he served as a senior consultant for several years with McKinsey & Company, Inc., where he directed a number of major
performance improvement projects for large international companies. In addition, from 1992-94 Mr. Dee served as Chief
Operating Officer and as a director of Waldon Laboratories (now AVAX Technologies, Inc.).
Mr. Dee has an M.S. in chemical engineering from Stanford University and an M.B.A. from Harvard University.
''I was very impressed with Mr. Dee's accomplishments during his short tenure at Genta and believe Procept will benefit from
his leadership,'' said Michael Weiss, Procept Chairman. ''I want to thank Stan Erck for all his efforts on behalf of the
Company and to wish him well in his future endeavors.''
Procept, Inc., located in Cambridge, MA, is engaged in the development of novel drugs for the prevention of HIV and other
infectious diseases through its lead product, PRO2000 Gel.
______________________________________________________________________
"He was most recently interim Chief Executive Officer of Genta Incorporated [Nasdaq:GNTA - news], where he led an intensive six-month corporate turnaround." I guess he wasn't talking about Genta's stock price! |
